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Abstract
Background: Primary percutaneous coronary intervention (PCI) is recommended for  
ST-segment elevation myocardial infarction (STEMI) patients even when the patient must be  
transported to a PCI-capable hospital. This study aimed to evaluate the long-term clinical 
outcomes of STEMI patients who were transferred for primary PCI compared to patients who 
arrived directly to PCI-capable hospitals.
Methods: A total of 3,576 STEMI patients with less than 12 h of symptom onset-to-door time 
from the Korea Acute Myocardial Infarction Registry were divided into transfer (n = 2,176) 
and direct-arrival (n = 1,400) groups according to their status. The primary outcome was 
the composite of major adverse cardiac event (MACE), defined as death, non-fatal myocardial 
infarction, and revascularization at 1 year.
Results: In the transfer vs. the direct-arrival group, the median symptom onset-to-firstmedical 
contact time was significantly shorter (60 vs. 80 min, p < 0.001), but the median symptom 
onset-to-door time was significantly longer (194 vs. 90 min, p < 0.001). The median door-to-
balloon time was significantly shorter in the transfer group vs. the direct-arrival group (75 vs. 
91 min, p < 0.001). Total death and the composite of MACE were not significantly different 
during hospitalization (5.1 vs. 3.9%, p = 0.980; 5.4 vs. 4.8%, p = 0.435, respectively) and at 
1-year (8.2 vs. 6.6%, p = 0.075; 13.7 vs. 13.9%, p = 0.922, respectively).
Conclusions: Transferring STEMI patients to PCI-capable hospitals with a time delay did 
not affect clinical outcomes after 1 year. This study suggests that inter-hospital transfer should 
be encouraged even with delay for STEMI patients who require primary PCI in areas with  
a similar geographic accessibility. (Cardiol J 2016; 23, 3: 289–295)
Keywords: transfer, myocardial infarction, comparative effectiveness research, 
percutaneous coronary intervention
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Introduction
Rapid reperfusion by primary percutaneous 
coronary intervention (PCI) is the preferred strat-
egy for treating patients with ST-segment eleva-
tion myocardial infarction (STEMI) [1]. Guidelines 
recommend that reperfusion therapy with primary 
PCI should be administered as soon as possible to 
all eligible patients with STEMI. Delays in door-to-
balloon times are associated with increased mortal-
ity [2–4]. Guidelines recommend a door-to-balloon 
time of 90 min or less [5, 6]. Unfortunately, in the 
United States, only 25% of hospitals are capable 
of performing PCI [7]. Therefore, if a patient with 
STEMI arrives at a non-PCI-capable hospital, they 
should be transferred to a PCI-capable hospital for 
primary PCI if the anticipated first medical contact-
to-device time at that hospital does not exceed 
120 min [5, 6]. In fact, only 12% of transferred pa-
tients were treated with PCI within 90 min of the 
time from the first medical contact [8]. Therefore, 
patient transfer can be a cause of significantly 
delayed treatment.
However, several studies have shown that 
pre-hospital electrocardiographic diagnosis and 
direct referral to PCI-capable hospitals decrease 
the time delay in treating patients with STEMI 
[1, 8, 9]. Quality improvement strategies have 
reduced door-to-balloon times for direct-arrival 
patients with STEMI undergoing primary PCI. 
Nevertheless, bypassing the local hospital is not 
always realistic, and many STEMI patients are still 
required to go through inter-hospital transfer for 
primary PCI.
We examined patients with STEMI who were 
registered in the Korea Acute Myocardial Infarction 
Registry (KAMIR). The aim of this study was to 
assess the clinical differences between transferred 
patients and direct-arrival patients. In addition, we 
aimed to evaluate the long-term clinical outcomes 
of patients with STEMI that were either trans-
ferred for primary PCI or direct-arrival patients.
Methods
Study population and study design
We analyzed data from the KAMIR database. 
KAMIR is a prospective, multicenter, observational 
online registry designed to survey the epidemiol-
ogy, management, clinical features, and prognosis 
of acute myocardial infarction (MI) patients in Ko-
rea, and it is supported by the Korean Circulation 
Society [10, 11]. A total of 50 hospitals in Korea 
are enrolled in KAMIR. These hospitals are high-
volume centers with facilities for PCI and on-site 
cardiac surgery. This study was approved by the 
ethics committee at each participating institution. 
All patients provided informed consent to partici-
pate before enrollment.
A total of 14,885 consecutive patients admitted 
between November 2005 and July 2007 with acute 
MI were included in the KAMIR, and 13,003 patients 
were confirmed as having MI at discharge. Howev-
er, 4,516 patients were excluded due to missing or 
invalid symptom-to-door times or invalid door-to- 
-balloon times. Among the remaining 8,487 pa-
tients, 5,650 patients were diagnosed with STEMI 
and 2,837 patients were diagnosed with non-STE-
MI. Of the STEMI patients, 2,068 patients were 
excluded due to a symptom-to-door time > 12 h, 
a symptom-to-first-medical-contact time > 12 h, or 
a door-to-balloon time > 6 h. In addition, data on 
6 patients were missing. Therefore, 3,582 patients 
were included in the final study population, which was 
divided into two groups: Group 1: those who were 
transferred to a PCI-capable hospital (n = 2,176) 
and Group 2: those who arrived directly at a PCI-
-capable hospital (n = 1,400). A flow chart of study 
population selection is presented in Figure 1. In 
this study, we analyzed baseline characteristics 
and then studied angiographic findings, mortality, 
and morbidity for 1 year.
The diagnosis of acute MI was based on clini-
cal presentation, electrocardiographic findings, and 
levels of cardiac enzymes. Patients were diagnosed 
with STEMI when they had new, or presumed 
new, ST-segment elevation of at least 1 mm seen 
in any location, a new left bundle-branch block 
on the index, or a subsequent electrocardiogram 
(ECG) with at least 1 positive cardiac biochemical 
marker of necrosis (including creatine kinase-MB 
and troponins I and T) [12].
Statistical analysis
Data are expressed as mean ± standard devia-
tion for continuous variables and percentages for 
categorical variables. Differences in the means of 
continuous measurements were tested by either 
the Student’s t-test or ANOVA. Analyses of dis-
crete variables were performed using the c2 test. 
All comparison between baseline characteristics 
was assessed with the ANOVA for continuous vari-
ables, and with the c2 test for categorical variables. 
For clinical outcomes, an F-test was performed to 
test whether major adverse cardiac events (MACE, 
percentage) between the transfer and direct- 
-arrival groups were different. In-hospital, 1-, 6-, and 
12-month MACE were evaluated by comparing the 
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mean values (percentage) using ANOVA. A value 
of p < 0.05 was considered significantly significant.
Results
Baseline patient characteristics
The 3,576 patients with STEMI who under-
went primary PCI between November 2005 and 
July 2007 were divided into two groups. Of these 
patients, 2,176 (60.9%), who arrived at a non-PCI-
-capable hospital and were transferred to a PCI-ca-
pable hospital, were assigned to the transfer group. 
A group of 1,400 (39.1%) patients who arrived di-
rectly to PCI-capable hospital were assigned to the 
direct-arrival group. There were some differences 
in the baseline patient characteristics between the 
transfer and direct-arrival groups. Compared to 
the direct-arrival group, transfer group patients 
were more likely to be older and male. In addition, 
43% of the transferred patients had hypertension, 
23% had diabetes, and 7% had dyslipidemia. In the 
direct-arrival group, 42% of patients had hyperten-
sion, 24% had diabetes, and 10% had dyslipidemia. 
There was a statistically significant difference in 
all of these parameters (Table 1). In contrast, there 
was no statistically significant difference in other 
parameters, such as smoking status or body mass 
index (Table 1).
Treatment delay
Treatment delay parameters are shown in 
Figure 1. Over the 2-year study period, the patients 
in the transfer group had shorter symptom onset-
-to-first medical contact times compared to patients 
in the direct-arrival group (60 vs. 80 min, p < 0.001). 
Also, the door-to-balloon time was significantly 
shorter in patients in the transfer group compared 
to those in the direct-arrival group (75 vs. 91 min, 
p < 0.001). However, patients in the transfer group 
had a significantly longer symptom onset-to-door 
time at PCI-capable centers compared to direct-
-arrival patients (194 vs. 90 min, p < 0.001). In 
addition, the symptom onset-to-balloon time was 
significantly longer for patients in the transfer 
group compared to the direct-arrival group (283 
vs. 205 min, p < 0.001).
Figure 1. Flow chart of the study population selection. A total of 13,003 patients were confirmed as ST-segment elevation 
myocardial infarction (STEMI) or non-STEMI (NSTEMI) at discharge and recruited for this study. However, 4,516 patients 
were excluded due to a symptom-to-door time (S-D) < 0, symptom-to-first medical contact time (S-1st MCT) < 0, door-to-
-balloon time (D-B) < 0, or symptom-door-to-first medical contact < 0. Out of the remaining 8,487 patients, 5,650 patients 
were STEMI patients and 2,837 patients were NSTEMI patients. In STEMI patients, 2,068 patients were excluded because of 
a symptom-to-door time > 12 h, symptom-to-first medical contact time > 12 h, door-to-balloon time > 6 h, and 
6 were missing. Ultimately, 3,582 patients were divided into two groups based on their status as transfer or non-
-transfer.
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Table 2. Angiographic and procedural characteristics.
Variable Transfer group  
(n = 2,176)
Direct-arrival group  
(n = 1,400)
P
Extent of CAD: 0.275
1 vessel disease 1084 (50.1%) 669 (48.1%)
2 vessel disease 627 (29.0%) 394 (28.3%)
3 vessel disease 413 (19.1%) 303 (21.8%)
Left main disease 38 (1.8%) 25 (1.8%)
Culprit lesion: 0.368
Left anterior descending 1107 (51.1%) 677 (48.7%)
Left circumflex 212 (9.8%) 150 (10.8%)
Right coronary artery 826 (38.2%) 545 (39.2%)
Left main 20 (0.9%) 18 (1.3%)
Baseline TIMI flow grade: 0.01
0 1388 (64.9%) 825 (60.1%)
1 178 (8.3%) 149 (10.9%)
2 295 (13.8%) 201 (14.7%
3 279 (13.0%) 197 (14.4%)
Stent implanted 2038 (93.7%) 1304 (93.1%) 0.828
Drug-eluting stent 2028 (94.1%) 1286 (92.9%) 0.136
Number of stents implanted per patients 1.39 (0.73%) 1.35 (0.69%) 0.105
Procedural success 2068 (96.0%) 1329 (96.2%) 0.685
CAD — coronary artery disease; TIMI — Thrombolysis in Myocardial Infarction
Table 1. Baseline characteristics.
Variable Transfer group
(n = 2,176)
Direct-arrival group
(n = 1,400)
P
Age [year] 61.83 ± 12.7 60.76 ± 12.81 0.014
Male sex 599 (27.55%) 322 (23.02%) 0.002
Body mass index [kg/m2] 23.96 ± 3.35 24.08 ± 3.23 0.290
Risk factors
Hypertension 938 (43.1%) 659 (41.7%) 0.044
Diabetes mellitus 499 (22.9%) 331 (23.6%) 0.046
Dyslipidemia 162 (7.4%) 142 (10.1%) 0.017
Smoking 1375 (63.4%) 853 (61.4%) 0.216
Symptom-to-first medical contact time [min] 60.00 (30.00, 150.00) 80.00 (35.00, 182.00) < 0.001
Symptom-to-door time [min] 194.00 (121.00, 305.00) 90.00 (47.25, 191.00) < 0.001
Door-to-balloon time [min] 75.00 (57.00, 102.00) 91.00 (67.00, 129.00) < 0.001
Symptom-to-balloon time [min] 283.00 (200.00, 406.00) 205.00 (141.00, 315.00) < 0.001
Killip class: 0.831
I 1590 (74.4%) 1015 (74.3%)
II 270 (12.6%) 184 (13.5%)
III 123 (5.8%) 72 (5.3%)
IV 154 (7.2%) 95 (7.0%)
Maximum troponin I [ng/mL] 72.52 ± 99.91 75.71 ± 339.52 0.771
B-type natriuretic peptide [pg/mL] 357.55 ± 51,908.35 415.88 ± 1,364.86 0.615
Serum creatinine [mg/dL] 1.07 ± 0.73 1.12 ± 0.85 0.028
Left ventricular ejection fraction [%] 51.30 ± 17.56 51.10 ± 11.79 0.721
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Angiographic and procedural characteristics
Angiographic and procedural characteristics 
are presented in Table 2. In the transfer and direct 
arrival groups, 93.7% and 93.1% of patients under-
went stent implantation (p = 0.828). Drug-eluting 
stents were used in both the transfer group (94.1%) 
and direct-arrival group (92.9%, p = 0.136). The pro-
cedural success rate was similar in the transfer and 
direct-arrival groups (96.0% vs. 96.2%, p = 0.685). 
Except for the baseline Thrombolysis in Myocar-
dial Infarction (TIMI) flow grade, which showed 
a statistical difference, the other angiographic and 
procedural characteristics were similar between 
the transfer and direct-arrival groups.
Clinical outcomes
The incidence of MACE during the follow-up 
period according to time-to-PCI is shown in Table 3. 
In the transfer and direct-arrival groups, the 
patients’ incidence of composite MACE in 
the hospital was 5.4% and 3.9%, respectively 
(p = 0.435). The incidence of composite MACE, 
death, non-fatal MI, and revascularization were 
not statistically different between the groups. 
Also, there were no significant differences in 
1-month MACE (7.4% vs. 7.7%, p = 0.766), 
6-month MACE (11.1% vs. 11.9%, p = 0.433), 
and 1-year MACE (13.7% vs. 13.9%, p = 0.922) 
in each group.
Table 3. Clinical outcomes.
Variable Transfer group  
(n = 2176)
Direct-arrival group  
(n = 1400)
P
In-hospital
Death 103 (5.1%) 51 (3.9%) 0.980
Non-fatal MI 5 (0.2%) 1 (0.1%) 0.252
Revascularization: 13 (0.6%) 9 (0.6%) 0.865
Re-PCI 5 (0.2%) 0 (0.0%) 0.073
CABG 8 (0.4%) 9 (0.6%) 0.243
MACE 117 (5.4%) 67 (4.8%) 0.435
1-month
Death 118 (5.9%) 67 (5.1%) 0.349
Non-fatal MI 13 (0.6%) 9 (0.7%) 0.891
Revascularization: 35 (1.6%) 26 (1.9%) 0.575
Re-PCI 23 (1.1%) 12 (0.9%) 0.554
CABG 12 (0.6%) 14 (1.0%) 0.123
MACE 162 (7.4%) 108 (7.7%) 0.766
6-month
Death 138 (6.9%) 82 (6.3%) 0.487
Non-fatal MI 16 (0.8%) 12 (0.9%) 0.714
Revascularization: 93 (4.3%) 70 (5.0%) 0.310
Re-PCI 80 (3.7%) 56 (4.0%) 0.622
CABG 15 (0.7%) 15 (1.1%) 0.221
MACE 241 (11.1%) 167 (11.9%) 0.433
12-month
Death 172 (8.2%) 89 (6.6%) 0.075
Non-fatal MI 17 (0.8%) 16 (1.2%) 0.276
Revascularization: 126 (5.8%) 89 (6.4%) 0.487
Re-PCI 110 (5.1%) 76 (5.4%) 0.624
CABG 18 (0.8%) 15 (1.1%) 0.456
MACE 299 (13.7%) 194 (13.9%) 0.922
CABG — coronary artery bypass grafting; MACE — major adverse cardiac events; MI — myocardial infarction; PCI — percutaneous coronary 
intervention
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Discussion
We evaluated the relationship between clini-
cal outcomes and transfer to hospitals with PCI 
capability in STEMI patients. The present study 
has several major findings. First, compared to the 
direct-arrival group, the symptom-onset-to-first 
medical contact time and door-to-balloon time 
were significantly shorter in the transfer group. 
However, the symptom onset-to-door time was 
longer in the transfer group than in the direct-
arrival group. Therefore, the symptom-to-balloon 
time was significantly longer in the transfer group 
compared to the direct-arrival group. In the case 
of transfer, there is time to prepare an appropri-
ate treatment before patient arrival. Therefore, 
the door-to-balloon time was significantly shorter 
in the transfer group. Importantly, however, the 
total death and the composite of MACE did not 
differ significantly both during hospitalization 
and after 1 year. Transferring STEMI patients to 
a PCI-capable hospital even with an acceptable time 
delay resulted in a modest increase in ischemia 
time, but did not affect clinical outcomes at 1-year. 
Therefore, this study suggests that inter-hospital 
transfer should be encouraged even with delay for 
STEMI patients who require primary PCI.
Primary PCI is the best treatment option for 
reperfusion. Previous studies have shown that 
primary PCI is superior to fibrinolytic therapy in 
reducing death, non-fatal reinfarction, and stroke 
[13–15]. In addition, multiple European studies 
have demonstrated that transfer of patients to PCI- 
-capable hospitals is associated with lower mortal-
ity compared to onsite fibrinolytic therapy [16–18]. 
These studies asserted that patients with STEMI, 
even when first admitted to a non-PCI-capable 
hospital, should be transported to a PCI-capable 
hospital. Importantly, Widimsky et al. [18] showed 
that long distance transport from a community 
hospital to a tertiary PCI center in the acute phase 
of acute MI is safe. This study was conducted in 
the Czech Republic. Our study showed similar 
results, which may be due to the fact that Korea’s 
geographic characteristics may be similar to those 
of the Czech Republic.
Several studies show that delaying primary 
PCI increases mortality risk and results in poor 
clinical outcomes [3, 4]. Pinto et al. [19] showed 
in a large analysis of STEMI transfer patients that 
the mortality benefit of primary PCI over on-site 
fibrinolysis disappears when the PCI-related de-
lay (door-to-balloon time minus door-to-needle 
time, in matched pairs) was 120 min or longer. 
Accordingly, many studies have made an effort 
to reduce the door-to-balloon time. Some studies 
suggest skipping local hospitals in favor of direct 
referral to PCI-capable hospitals via pre-hospital 
electrocardiogram diagnosis [8, 9]. This strategy is 
very effective and shows better clinical outcomes. 
However, in many situations, emergency medi-
cal services do not have well-trained emergency 
medical services providers and cannot employ this 
strategy.
Currently, many patients with STEMI are 
transferred to PCI-capable hospitals. Our study 
showed that transfer to PCI-capable hospitals 
with a short delay did not increase the mortality 
rate. Because of the geographical characteristics 
in South Korea, the time difference was not sig-
nificantly different between transfer patients and 
direct-arrival patients. In the case of countries 
with more expansive cities, such as America or 
Europe, there could be different results. Therefore, 
inter-hospital transfer of STEMI patients should 
be encouraged even with an acceptable time delay 
for primary PCI in areas with similar geographic 
characteristics.
Limitations of the study
Our study has several limitations. First, this is 
an observational study using data from a prospec-
tively gathered nationwide registry. Our study was 
not a randomized control study, and there were sig-
nificant differences in the baseline characteristics 
and angiographic characteristics. Second, we only 
have data on patients with STEMI who presented 
to the hospital. Data on those who did not present 
to the hospital, who died at home, or who died dur-
ing transport to the hospital were not available for 
analysis. Hence, there is a survival bias that could 
have confounded our results. Third, in this study, 
only 1-year clinical outcomes were followed. More 
data are needed on long-term outcomes in patients 
with STEMI.
Conclusions
According to the KAMIR data, approximately 
60% of patients with STEMI initially arrive at 
non-PCI capable hospitals and are transferred to 
PCI-capable hospitals. Transferring STEMI pa-
tients to PCI-capable hospitals delays reperfusion 
time. However, it does not affect clinical outcomes 
at 1-year. Our results suggest that inter-hospital 
transfer of STEMI patients should be encouraged 
even with an acceptable delay for primary PCI in 
areas with a similar geographic accessibility.
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